microdose glp-1 benefits Medical Weight Loss with GLP-1s - Everything you need to know! GLP-1 Microdosing: Risks, Benefits and

Safety data is limited to the preclinical studies, where no adverse events were reported at therapeutic doses during the 11-week treatment period the longest published study duration

LMICs Low- and middle-income countries HICs High-income countries NK cells Natural killer cells TNF- Tumor necrosis factor- IL-1 Interleukin-1 IL-6 Interleukin-6 TLR-4 Toll-like receptor-4 LPS Lipopolysaccharide NLRP3 NOD-like receptor protein 3 ROS Reactive Oxygen Species NO Nitric oxide SIM Sepsis-induced Myopathy GLP-1R Glucagon-like peptide-1 receptor GLP-1 Glucagon-like peptide-1 GLP-1RA Glucagon-like peptide-1 receptor agonist PKA Protein kinase A PLC Phospholipase C ERK1/2 Extracellular signal-regulated kinase 1 and 2 DPP-4 Dipeptidyl peptidase-4 IL-1 Interleukin-1 MCP-1 Monocyte Chemoattractant Protein-1 IL-10 Interleukin-10 iNOS Inducible nitric oxide synthase eNOS Endothelial nitric oxide synthase CRP C-reactive protein MDA Malondialdehyde 8-OHdG 8-hydroxy-2deoxyguanosine ICU Intensive Care Unit SOD Superoxide dismutase GPx Glutathione peroxidase Nrf2 Nuclear factor erythroid 1-related factor 2 SAE Sepsis-associated encephalopathy mTOR Mammalian target of rapamycin DPP-4is Dipeptidyl peptidase-4 inhibitors Glossary References 1

Pharmacian 10, 231238

Goldszmid RS